Our Clinical Trials

Here you can find descriptions of key transplantation clinical trials offered at Memorial Sloan-Kettering. For eligibility and contact information, select a study from the list below.

Clicking a link below will scroll the
page down to the relevant section

Sibling and Unrelated Volunteer Transplant Protocols
Umbilical Cord Blood Transplant Protocols
Autologous (Patient's Own Cells) Transplant Protocols
Post-Transplant Protocols

Sibling and Unrelated Volunteer Transplant Protocols

A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and Stem Cell Transplantation in Patients with B-cell Non-Hodgkin's Lymphoma
Castro-Malaspina, Hugo, MD

[Protocol 06-150]
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies
Boulad, Farid, MD

[Protocol 06-125]
A Phase II Pilot Trial of Hematopoietic Stem Cell Transplantation with Total Body Irradiation, Cyclophosphamide & Fludarabine to Treat Patients with Fanconi Anemia Lacking a Genotypically Identical Donor
Boulad, Farid, MD

[Protocol 01-062]
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS
Castro-Malaspina, Hugo, MD

[Protocol 08-008]
A Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants after a Myeloablative Preparative Regimen for Adult Patients with Lymphohematopoietic Disorders
Jakubowski, Ann, MD, PhD

[Protocol 01-070]
A Phase II Trial of Intravenous Myeloablative Chemotherapy Followed by an Allogeneic Hematopoietic Stem Cell Transplant from a Matched Relative to Treat High-Risk Ewing's Sarcoma Family Tumors
Prockop, Susan, MD

[Protocol 05-059]
A Phase II Trial of T Cell Depleted Peripheral Blood Stem Cell Transplantation to Treat Patients with AML in First or Second Complete Remission
O'Reilly, Richard, MD

[Protocol 06-005]
A Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin's Lymphoma
Perales, Miguel-Angel, MD

[Protocol 07-147]
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation from HLA-Compatible Unrelated Donors in Severe Aplastic Anemia
Castro-Malaspina, Hugo, MD

[Protocol 06-056]

Top

Umbilical Cord Blood Transplant Protocols

A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with B cell Lymphoid Malignancies
Barker, Juliet, MBBS

[Protocol 06-066]
A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adults with Hematological Cancers
Barker, Juliet, MBBS

[Protocol 07-072]
A Reduced Intensity Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with Acute Leukemia or Myelodysplasia
Barker, Juliet, MBBS

[Protocol 08-087]
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy
Barker, Juliet, MBBS

[Protocol 06-014]

Top

Autologous (Patient's Own Cells) Transplant Protocols

A Phase II Study of Dose-Escalated Rituximab and ICE for Patients with Primary Refractory and Poor-Risk Relapsed Aggressive B-cell Non-Hodgkin's Lymphoma Undergoing Second-Line Therapy Prior to Stem Cell Transplantation
Moskowitz, Craig, MD

[Protocol 03-075]
A Phase II Study of Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue in Newly Diagnosed Primary CNS Lymphoma
Abrey, Lauren, MD

[Protocol 04-129]
A Phase II Trial of Risk-Adapted High-Dose Chemoradiotherapy and Autologous Stem Cell Transplantation for Patients with Relapsed and Primary Refractory Hodgkin's Lymphoma
Moskowitz, Craig, MD

[Protocol 04-047]

Top

Post-Transplant Protocols

A Phase I Study of CYT 107 in Recipients of HLA-Matched T Cell-Depleted Peripheral Blood Stem Cell or Bone Marrow Transplants
VanDenBrink, Marcel, MD, PhD

[Protocol 07-127]
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
O'Reilly, Richard, MD

[Protocol 95-024]
A Phase II Study of GM-CSF (Sargramostim) and Rituximab Following Autologous Transplantation for Relapsed Follicular Lymphoma
Moskowitz, Craig, MD

[Protocol 07-085]
A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant
Hsu, Katharine, MD, PhD

[Protocol 07-035]
A Phase III Study of Maintenance Therapy with CC-5013 or Placebo After Autologous Stem Cell Transplantation for Multiple Myeloma
Hassoun, Hani, MD

[Protocol 05-080]
A Phase III Study to Evaluate Prochymal^TM (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion in Combination with Corticosteroids for the Treatment of Newly Diagnosed Acute GvHD
Papadopoulos, Esperanza, MD

[Protocol 08-083]
A Study Evaluating the Effectiveness of Leuprolide for Enhancing Immune Function After Autologous Stem Cell Transplantation
Landau, Heather, MD

[Protocol 07-046]

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2009 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org